Sai Life Sciences (SAILIFE) Q3 24/25 earnings summary

Executive summary

• Achieved 15% year-over-year revenue growth in Q3 FY 2025, with CDMO and CRO segments contributing 60% and 40% of total revenue, respectively; strong quarterly performance driven by integrated CRDMO model and expanding global presence.

• EBITDA grew 19% year-over-year with margin expansion; PAT increased 36% year-over-year, supported by operational efficiencies and a robust order pipeline.

• Board approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024; statutory auditors issued unmodified review reports.

• Company completed its IPO and listed shares on NSE and BSE on 18 December 2024.

• Focus remains on strengthening service offerings, expanding into new modalities, and driving operational excellence for sustainable stakeholder value.

Financial highlights

• Q3 FY 2025 consolidated revenue reached INR 440 crore (₹4,397.78 million), up 15% year-over-year; EBITDA at ₹124 crore, up 19% YoY; PAT at ₹54 crore, up 36% YoY.

• Nine-month FY25 consolidated revenue at ₹1,142 crore (₹11,150.63 million), up 9% YoY; EBITDA at ₹264 crore, up 50% YoY; PAT at ₹82 crore, up 207% YoY.

• EBITDA margin improved to 28.3% in Q3 FY25 from 27.5% in Q3 FY24; profit before tax rose 35% to INR 72 crore.

• Basic EPS (consolidated) for the quarter: Rs. 2.89; nine months: Rs. 4.40.

• Operating cash flow for nine months was INR 246 crore (92%-93% of EBITDA); free cash flow was INR 21 crore.

Outlook and guidance

• Long-term aspiration for 15%-20% revenue CAGR and EBITDA margin of 28%-30% over the next 3-5 years.

• Q4 and H2 are expected to be stronger due to seasonality; margin improvement expected as commercial products scale.

• Sustained growth momentum expected, supported by a strong order pipeline and ongoing investments in infrastructure and capabilities.

• CapEx for FY 2025 expected to reach INR 400-425 crore; FY 2026 CapEx guidance to be provided later.

• Anticipates reduction in interest costs in the next quarter following full repayment of planned IPO-related debt.